Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05960890
Recruiting Not applicable

Cohort Study of Chronic Heart Failure

NCT05960890 · tracked via the Priya Life Science China tracker
Sponsor
Jiangsu Taizhou People's Hospital
Phase
Not applicable
Started
2023-06-08
Last updated
2026-05-20

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

Remote monitoring assisted by community physicians

Remote monitoring assisted by community physicians: Patients upload data such as wristband data, blood pressure, weight through their mobile phones, while physicians can check the data on the platform. Upon detecting alerts, community physicians review participant-related medical information, conduct structured symptom assessments via "StarNet Home" platform/phone within 2 hours, and initiate protocol-guided interventions (e.g., diuretic adjustment for fluid overload).

Study summary

The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years; 2. Fulfill at least one of the following criteria：①History of chronic heart failure;②New-onset heart failure with LVEF \<50%；③New-onset heart failure with LVEF≧50%，E/e'≧15 and BNP\>400 pg/mL/NT-proBNP(\<50 years, \>450 pg/mL; 50\~75 years, \>900 pg/mL; \>75 years, \>1800 pg/mL) 3. Etiology: dilated cardiomyopathy, hypertensive heart disease, ischaemic cardiomyopathy, Non-severe valvular heart disease； 4. Primary post-discharge therapy: oral medication; 5. Sign the informed consent form. Exclusion Criteria: 1. Patients with renal failure (Ccr\<30ml/min) or patients on dialysis therapy; 2. Various correctable secondary causes of cardiac insufficiency including hyperthyroid heart disease, anaemic heart disease, uncorrected congenital heart disease; severe valvular heart disease (including severe stenosis or closure of organic aortic and mitral valves); 3. Patients with indications for pacemaker implantation but have not received a pacemaker implant; 4. Patients with chronic obstructive pulmonary disease accompanied by type II respiratory failure. 5. Patients who cannot understand and sign an informed consent form. 6. Patients with mental illness, pregnant women, and other special populations.

Primary outcome measure(s)

  • incidence of composite event (cardiovascular mortality, unplanned HF hospitalization, emergency HF intervention) — 2 years
    Cardiovascular disease death, heart failure readmission and emergency HF intervention are three endpoint events, with either occurring as the primary endpoint

Trial sites (1)

FacilityCityRegionStatus
Taizhou People's Hospital affiliated to Nanjing Medical University Taizhou Jiangsu Recruiting

More Jiangsu Taizhou People's Hospital trials in China

Survey of Knowledge, Practice, and Recommendation Behaviors Regarding Healthy Lifestyles Among Healthcare Workers Starting soon
Auricular Acupuncture Therapy Administered by Village Doctors Improves Sleep Quality in Elderly Patients With Comorbid Diabetes Mellitus and Hypertension Recruiting
MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base Morphology Recruiting
Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China Recruiting
A Village Doctor-led Telehealth Supported Trial of Heart Failure Prevention in AF Patients: MIRACLE-AF 2 (Heart Failure Prevention) Recruiting

Other trials for the same condition

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting
A Clinical Study of HRS-7156 in Healthy Participants Recruiting
Biomarkers for Left Ventricular Reverse Remodeling in Heart Failure (REVERT-HF) Recruiting
31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05960890 on ClinicalTrials.gov ↗ ← All trials in China